References
- Greenough A, Khetriwal B. Pulmonary hypertension in the newborn. Paediatr Resp Rev 2005;6:111–116.
- Walsh-Sukys MC, Tyson JE, Wright LL, Bauer CR, Korones SB, Stevenson DK, Verter J, Stoll BJ, Lemons JA, Papile LA, Shankaran S, et al Persistent pulmonary hypertension of the newborn in the era before nitric oxide: practice variation and outcomes. Pediatrics 2000;105:14–20.
- Geggel RL, Reid LM. The structural basis of PPHN. Clin Perinatol 1984;11:525–549.
- Steinhorn RH. Nitric oxide and beyond: new insight and therapies for pulmonary hypertension. J Perinatol 2008;28:S67–S71.
- Rosenzweig EB, Barst RJ. Pulmonary arterial hypertension in children: a medical update. Indian J Pediatr 2009;76:77–81.
- Leibovitch L, Matok I, Paret G. Therapeutic applications of sildenafil citrate in the management of paediatric pulmonary hypertension. Drugs 2007;67:57–73.
- Atz AM, Lefler AK, Fairbrother DL, Uber WE, Bradley SM. Sildenafil augments the effect of inhaled nitric oxide for postoperative pulmonary hypertensive crises. J Thorac Cardiovasc Surg 2002;12:628–629.
- Noori S, Friedlich P, Wong P, Garingo A, Seri I. Cardiovascular effects of sildenafil in neonates and infants with congenital diaphragmatic hernia and pulmonary hypertension. Neonatology 2007;91:92–100.